

03 November 2025

2025/26 Invitation to Tender

Pharmac's 2025/26 Invitation to Tender (2025/26 ITT) has been released today.

If you have already registered your e-mail address with Pharmac's tendering e-portal you can access the 2025/26 ITT in the e-portal in Current Tenders.

[Go to the In-Tend e-portal](#)

If you have not registered your company with the e-portal, and you would like to participate in the 2025/26 ITT, please register online.

[Register your company with the In-Tend e-portal](#)

A complete copy of the 2025/26 ITT is available on the Pharmac website. We will not be posting out any hard copies of the 2025/26 ITT.

[Find the 2025/26 ITT on our website](#)

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to Pharmac no later than 4 pm (New Zealand time) on Monday 15 December 2025.

We expect to commence the evaluation of bids in January 2026. In preparation for this, please note that we will begin requesting product samples in December before Christmas. To help us avoid delays in this year's tender process, we would appreciate it if you could ensure that any requested samples are available by late January to early February. Thank you in advance for your cooperation.

Changes to the 2025/26 ITT product list

Please note that the product list (Schedule Two) consulted on in July 2025 has changed. Some products have been added, removed or amended either as a result of:

- clinical advice received (e.g. from the Tender Clinical Advisory Committee); and/or
- feedback received on the draft 2025/26 ITT; and/or
- a review of unresolved bids from previous tenders.

The following items have been added to the 2025/26 ITT:

Chemical Name	Line Item
Alendronate sodium	Tab 70 mg
Bupivacaine hydrochloride with adrenaline	Inj 0.25% with 1:400,000 of adrenaline, 20 ml non-sterile pack
	Inj 0.5% with 1:200,000 of

Chemical Name	Line Item
	adrenaline, 20 ml non-sterile pack
Carboprost	Inj 250 mcg per ml, 1 ml
Carvedilol	Tab 6.25 mg
	Tab 12.5 mg
	Tab 25 mg
Clotrimazole	Soln 1%

Chemical Name	Line Item
Colecalciferol	Oral liq 188 mcg per ml (7,500 iu per ml)
Cyclosporine	Eye emulsion (strength greater than or equal to 0.05%)
	Eye oint (strength greater than or equal to 0.05%)
	Eye drops (strength greater than or equal to 0.05%)
Dapsone	Tab 25 mg
	Tab 50 mg
	Tab 100 mg
Dexamethasone with framycetin and gramicidin	Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml
Efavirenz with emtricitabine and tenofovir disoproxil (as a fumarate)	Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)
Efavirenz with emtricitabine and tenofovir disoproxil (as a maleate)	Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)
Esmolol hydrochloride	Inj 10 mg per ml, 10 ml vial
Famotidine	Tab 20 mg
	Tab 40 mg
Fenofibrate	Cap/tab 48 mg
	Cap/tab 145 mg
Fluconazole	Inj 2 mg per ml, 50 ml vial
	Inj 2 mg per ml, 100 ml vial
Glucagon hydrochloride	Inj 1 mg syringe kit
Haloperidol	Inj 5 mg per ml, 1 ml
Irinotecan	Inj 20 mg per ml, 5 ml
Ketamine	Inj 100 mg per ml, 2 ml vial
Lidocaine [lignocaine] hydrochloride with adrenaline	Inj 1% with adrenaline 1:100,000, 20 ml vial
	Inj 2% with adrenaline 1:200,000, 20 ml vial
Macitentan	Tab 10 mg

Chemical Name	Line Item
Midazolam	Inj 2.5 mg per ml, buccal syringe
	Inj 5 mg per ml, buccal syringe
	Inj 7.5 mg per ml, buccal syringe
	Inj 10 mg per ml, buccal syringe
Mitomycin C	Inj 2 – 5 mg
Mupirocin	Oint 2%
Nintedanib	Cap 100 mg
	Cap 150 mg
Octreotide	Inj 50 mcg per ml, 1 ml prefilled syringe
	Inj 100 mcg per ml, 1 ml prefilled syringe
	Inj 500 mcg per ml, 1 ml prefilled syringe
Oxybutynin	Tab 5 mg
Oxycodone hydrochloride	Tab immediate-release 5 mg
	Tab immediate-release 10 mg
	Tab immediate-release 20 mg
Potassium chloride	Inj 75 mg (1 mmol) per ml, 10 ml ampoule
Pyridostigmine bromide	Tab 60 mg
Ranitidine	Tab 150 mg
	Tab 300 mg
Rotigotine	Transdermal patch 2 mg per 24 hours
	Transdermal patch 4 mg per 24 hours
	Transdermal patch 6 mg per 24 hours
	Transdermal patch 8 mg per 24 hours
Sapropterin dihydrochloride (current access)	Tab soluble 100 mg
Sapropterin dihydrochloride (widened access)	Tab soluble 100 mg
Selexipag	Tab 200 mcg
	Tab 400 mcg
	Tab 600 mcg
	Tab 800 mcg
	Tab 1,000 mcg
	Tab 1,200 mcg
	Tab 1,400 mcg
	Tab 1,600 mcg
Sodium nitroprusside	Inj 50 mg vial
Sodium phosphate with phosphoric acid	Enema 10% with phosphoric acid 6.58%

Chemical Name	Line Item
Suxamethonium chloride	Inj 50 mg per ml, 2 ml prefilled syringe
Tadalafil	Tab 10 mg
	Tab 20 mg
Tafamidis	Cap 20 mg
	Cap 61 mg

Chemical Name	Line Item
Thiamine hydrochloride	Inj 100 mg per ml, 2 ml
Zonisamide	Cap 25 mg
	Cap 50 mg
	Cap 100 mg

The following items have been amended in the 2025/26 ITT:

Chemical Name	Line Item
Adapalene	Crm 0.1%
	Gel 0.1%
Ambrisentan (current access)	Tab 5 mg
	Tab 10 mg
Ambrisentan (widened access)	Tab 5 mg
	Tab 10 mg
Aspirin	Tab EC 100 mg
Calcium folinate	Inj 50 mg
	Inj 100 mg
	Inj 300 mg
	Inj 350 mg
	Inj 1 g
Cefuroxime sodium	Inj 250 mg
Ciprofloxacin	Tab 500 mg
	Tab 750 mg
Colecalciferol	Cap/tab 1.25 mg
Desmopressin acetate	Nasal spray 10 mcg per dose
Emulsifying ointment	Oint (pack size 200 g or less)
	Oint (pack size greater than 200 g)
Famotidine	Inj 10 mg per ml, 2 ml
Fluconazole	Cap 50 mg
	Cap 150 mg
	Cap 200 mg
Gemcitabine hydrochloride	Inj 1 g
Gliclazide	Tab 80 mg
Glucose [dextrose]	Inj 50%, 10 ml - 20 ml
	Inj 50%, 90 ml - 100 ml
Hyoscine (Scopolamine)	Patch 1 mg per 72 hours
Ibuprofen	Tab 200 mg, blister pack (pack size less than or equal to 20)
Intra-uterine device (Non-hormonal)	IUD Long
	IUD Medium
	IUD Short

Chemical Name	Line Item
Isosorbide mononitrate	Tab long-acting 60 mg
Ketoconazole (current access)	Shampoo 2%
Ketoconazole (widened access)	Shampoo 2%
Melphalan	Inj 50 mg vial
Methotrexate	Inj 100 mg per ml, 10 ml vial
Methylprednisolone aceponate	Crm 0.1%
	Oint 0.1%
Metronidazole	Tab 200 mg
	Tab 400 mg
Miconazole nitrate	Crm 2%
Morphine	Oral liq 1 mg per ml
	Oral liq 2 mg per ml
	Oral liq 5 mg per ml
	Oral liq 10 mg per ml
Olanzapine	Tab 2.5 mg
	Tab 5 mg
	Tab 10 mg
Paracetamol	Suppos 125 mg
	Suppos 250 mg
	Suppos 500 mg
Perindopril with amlodipine	Tab 5 mg with amlodipine 5 mg
	Tab 5 mg with amlodipine 10 mg
Pimecrolimus (current access)	Crm 1%
Pimecrolimus (widened access)	Crm 1%
Propranolol	Oral liq 4 mg per ml
Rifampicin with isoniazid and ethambutol and pyrazinamide	Tab/Cap 150 mg with isoniazid 75 mg and ethambutol 275 mg and pyrazinamide 400 mg
Rifampicin with isoniazid and pyrazinamide	Tab/Cap 150 mg with isoniazid 75 mg and pyrazinamide 400 mg

Chemical Name	Line Item
Suxamethonium chloride	Inj 50 mg per ml, 2 ml
Tacrolimus (current access)	Oint 0.1%
Tacrolimus (widened access)	Oint 0.1%
Thiotepa	Inj 15 mg Inj 100 mg

Chemical Name	Line Item
Timolol maleate	Eye drops 0.25% Eye drops 0.5%
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml
Tropicamide	Eye drops 0.5% Eye drops 1%

The following items that were included in consultation have been removed from the 2025/26 ITT:

Chemical Name	Line Item
Labetalol	Tab 100 mg Tab 200 mg
Oestriol	Crm 1 mg per g with applicator(s) Pessaries 500 mcg Tab 1 mg - 2 mg
Oxycodone hydrochloride	Oral liq 1 mg per mg
Pancreatic enzyme	Cap 150 mg Cap 175 mg Cap 300 mg Cap 420 mg

Additional Notes

Appropriate pack-size and packaging type

Where possible, Pharmac has identified Tender Items where there is a specific product preference in Schedule Two of the 2025/26 ITT document. For example (highlighted in red):

Allopurinol						
<u>Tab 100 mg</u>	32,673,262	\$587,792	\$0.0180	C H	5%	Preference for a scored tablet.
<u>Tab 300 mg</u>	24,033,966	\$1,081,528	\$0.0450	C H	5%	Preference for a scored tablet.

While Pharmac has taken all reasonable care in identifying these preferences, it makes no representation as to the accuracy of this information and accepts no liability for any errors or omissions. Suppliers should always undertake their own due diligence before submitting any tender bids.

Please note: we have historically indicated a preference for the pack size of Tender Items supplied in the community to be either a 30-day or 90-day pack. This improves dispensing efficiency and reduces wastage. We will be putting greater emphasis on packaging type and pack size in the future. There is a preference for bottle packs for tablets and capsules, where possible.

In this Tender we have identified specific packaging preferences for individual products in Schedule 2. We are aiming to expand this to a much wider range of products in future Tenders.

Oncology injectables

Health NZ hospitals are increasingly delivering chemotherapy treatment in satellite centers. These centers require compounded products to have a shelf-life greater than 24 hours. This accounts for delays in treatment transport and delivery. Therefore, Pharmac has indicated a preference for products with post-compounding stability data that is greater than 48 hours.

Ophthalmology Products (preservative-free)

Pharmac reserves its right to list a preservative-free product for a restricted market. This is indicated in Schedule Two of the 2025/26 ITT. However, where a tender product is preservative-free it would have the entire market.

Access criteria

Pharmac is tendering for current or widened access for some products. This is indicated in Schedule Two of the 2025/26 ITT document and details the potential access criteria. Please note any access criteria are indicative only. Pharmac reserves the right to amend these criteria.

Chemical Name	Line Item(s)
Adapalene	Crm 0.1% Gel 0.1%
Ketoconazole	Shampoo 2%
Pimecrolimus	Crm 1%
Rosuvastatin	Tab 10 mg Tab 20 mg Tab 40 mg Tab 5 mg

Chemical Name	Line Item(s)
Sapropterin dihydrochloride	Tab soluble 100 mg
Tacrolimus	Oint 0.1%
Vancomycin	Cap 125 mg Cap 250 mg

Data estimates for PCT injectable products included in the 2025/26 ITT

All usage figures are in mg, rounded to the nearest 100 mg, for the financial year ended 30 June 2025. For each chemical, the table shows:

- The number of vials purchased directly by Health NZ hospitals, and
- The total number of mg supplied through third party facilities. Note that this will also contribute to the total demand for vials listed in the Schedule.

Usage data for PCT injectable products

Chemical Name	Presentation	Total usage mg (vials)
Calcium folinate	Inj 50 mg vial	836,100 (16,721)
	Inj 100 mg vial	448,000 (4,480)
	Inj 300 mg vial	610,200 (2,034)
	Inj 350 mg vial	378,000 (1,080)
	Inj 1 g	7,000 (7)
	Compounding usage	493,100

Chemical Name	Presentation	Total usage mg (vials)
Docetaxel	Inj 80 mg vial	50,100 (627)
	Compounding usage	514,900
Gemcitabine hydrochloride	Inj 1 g	610,700 (611)
	Compounding usage	8,628,700
Irinotecan hydrochloride	Inj 20 mg per ml, 5 ml vial	27,960 (280)
	Compounding usage	1,912,900
Melphalan	Inj 50 mg vial	85,500 (1,710)
Methotrexate	Inj 100 mg per ml, 50 ml	433,200 (87)
	Inj 100 mg per ml, 10 ml vial	No data available.
	Compounding usage	3,805,500
Mitomycin C	Inj 2 mg – 5 mg	250 (50)
	Compounding usage	4,600
Paclitaxel	Inj 100 mg	1,800 (18)
	Inj 300 mg	36,600 (122)
	Compounding usage	1,690,600
Thiotepa	Inj 15 mg	11,400 (760)
	Inj 100 mg	17,200 (172)

Pharmac makes no representation as to the accuracy of this information or as to the level of sales or likely sales. While Pharmac has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information.

To be fair to all suppliers, we are unlikely to provide any further data relating to tender items while the 2025/26 ITT remains open.

More information

If you have any queries regarding the tender or require any assistance with the e-portal please contact the Tender Analysts (Stef Moir and Jade Matthews-Wanden) at tender@pharmac.govt.nz